Antianginal treatment of stable angina: focus on heart rate reduction
Abstract
The article is focused on modern approaches to heart rate reduction, as a new method for stable angina (SA) management. The algorhithm of SA pharmaceutical treatment, by the European Society of Cardiology (2006), is analyzed.
About the Author
Yu. M. Lopatin
Volgograd State Medical University, Volgograd Regional Cardiology Center. Volgograd
Russian Federation
Russian Federation
References
1. Diaz A., Bourassa M.G., Guertin M-C., et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.
2. Patel S.R., Breall J.A., Diver D.J., et al. Bradycardia is associated with development of coronary collateral vessels in humans. Coron Artery Dis 2000; 11:467-72.
3. Heidland U.E., Strauer B.E. Left ventricular muscle mass and eleva ed heart rate associated with coronary plaque distruption. Circulation 2001; 104: 1477-82.
4. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81.
5. Recommendation of the Task Force of the European Society of cardiology. Management of stable angina pectoris. Eur Heart J 1997; 18: 394-413.
6. Thadani U. Treatment of stable angina. Curr Opin Cardiol 1999; 14: 349-58.
7. Expert consensus document on b-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of cardiology. Eur Heart J 2004; 25: 1341-62.
8. Purcell Y., Fox K. Selective and specific If inhibition: new perspectives. Medicographia 2005; 27: 51-5.
9. Daly CA, Clements F, Lopez Sendoz JL, et al. The initial manage8 ment of stable angina in Europe, from the Euro Heart Survey. Eur Heart J 2005; 26: 1011822.
10. Daly C.A., Clements F., Lopez Sendoz J.L., et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006; 27: 1298-304.
11. Tendera M. If inhibition: from pure heart reduction to treatment of stable angina. Eur Heart J 2005; Suppl. H: H3-6.
12. Borer J.D., Fox K., Jalion P., et al. Antianginal and antiischemic effects of ivabradin, an If inhibitor in stable angina. Circulation 2003; 107: 817-23.
13. Ruzyllo W., Ford I., Tendera M., et al. Antianginal and antiischemic effects of If current inhibitor ivabradine compared to amlopdipine as monotherapy in patients with chronic stable angina: A 3-month randomized, controlled, double-blind, multicenter trial. Eur Heart J 2004; 25: Abstr 867.
14. Tardif J-C., Ford I., Tendera M., et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heat J 2005; 26: 2529-36.
15. Tardif J-C., Fox K., Tendera M., et al. Absence of rebound phenomenon after abrupt discontinuation of ivabradine, a new selective and specific If inhibitor, in patients with coronary artery disease. Eur Heart J 2005; 26: 580.
16. Diaz A., Tardif J-C. Clinical applications of exclusive heart rate reduction in emergence cardiology. Medicographia 2005; 27: 82-6.
Review
For citations:
Lopatin Yu.M. Antianginal treatment of stable angina: focus on heart rate reduction. Cardiovascular Therapy and Prevention. 2006;5(7):86-90. (In Russ.)
Views:
465
Email this article 
